Clinical trials: HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)

HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)

Expanded Access to Tipifarnib

• Available
• Age: 18 years and older
• Expanded access

Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL).

Trial name

Kuraoncology (NCT04809233)

Testing

Tipifarnib

Sponsor

Kura Oncology, Inc.